The development of a safe and efficient dengue vaccine represents a global challenge in public health. Chimeric dengue viruses (DENV) based on an attenuated flavivirus have been well developed as vaccine candidates by using reverse genetics. In this study, based on the full-length infectious cDNA clone of the well-known Japanese encephalitis virus live vaccine strain SA14-14-2 as a backbone, a novel chimeric dengue virus (named ChinDENV) was rationally designed and constructed by replacement with the premembrane and envelope genes of dengue 2 virus. The recovered chimeric virus showed growth and plaque properties similar to those of the parental DENV in mammalian and mosquito cells. ChinDENV was highly attenuated in mice, and no viremia was induced in rhesus monkeys upon subcutaneous inoculation. ChinDENV retained its genetic stability and attenuation phenotype after serial 15 passages in cultured cells. A single immunization with various doses of ChinDENV elicited strong neutralizing antibodies in a dose-dependent manner. When vaccinated monkeys were challenged with wild-type DENV, all animals except one that received the lower dose were protected against the development of viremia. Furthermore, immunization with Chin-DENV conferred efficient cross protection against lethal JEV challenge in mice in association with robust cellular immunity induced by the replicating nonstructural proteins. Taken together, the results of this preclinical study well demonstrate the great potential of ChinDENV for further development as a dengue vaccine candidate, and this kind of chimeric flavivirus based on JE vaccine virus represents a powerful tool to deliver foreign antigens.
D
engue has emerged as the most important mosquito-borne viral disease worldwide during the past decades. The spectrum of illness ranges from asymptomatic infections and dengue fever (DF) to severe and potentially life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Dengue is transmitted to humans by infected Aedes mosquitoes and maintained by a human-mosquito-human cycle of transmission in nature. The World Health Organization (WHO) estimates that over 50 million infections occur annually, with 25,000 to 50,000 cases of DHF, and there are over 2.5 billion persons at risk of infection in more than 100 countries throughout the tropical and subtropical regions (1) . In fact, the global health burden of dengue could be much higher than previously thought, and a recent modeling work revealed that 390 million people around the world were infected with this mosquito-borne virus in 2010 (2) . Currently, there is neither a licensed vaccine nor an effective and specific antiviral therapy for dengue. The four serotypes of dengue virus (DENV-1 to DENV-4) belong to the Flavivirus genus in the family Flaviviridae together with Japanese encephalitis virus (JEV), Yellow fever virus (YFV), West Nile virus (WNV), and tick-borne encephalitis virus (TBEV). Flaviviruses have an ϳ11-kb singlestranded positive-sense RNA genome that contains a single open reading frame (ORF) flanked by two untranslated regions (5= and 3= UTRs). The ORF encodes a single polyprotein, which is proteolytically processed into three structural proteins (C, prM, and E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The E glycoprotein is the principal antigen inducing protective immunity against virus infection, and it requires the coexpression of prM to acquire its native conformation.
All the nonstructural proteins are actively involved in viral genome replication, translation, and regulation. Due to the high degree of similarity among flaviviruses in genome organization, replication, and translation strategy, viable chimeric viruses have been rationally designed and generated by interchanging various genes among different flaviviruses (3) (4) (5) (6) by using reverse genetics. This kind of chimeric approach has been widely utilized in dengue vaccine development (6) (7) (8) (9) (10) (11) . The most advanced product of this kind is the ChimeriVax-Dengue (CYD) vaccine developed by Sanofi Pasteur, which was created based on the yellow fever vaccine strain 17D (YF-17D) (reviewed in reference 12). The protective efficacy of this tetravalent dengue vaccine in a phase 2b trial in Thailand was recently reported (13) , and large-scale phase 3 trials are ongoing (14) . Another chimeric dengue vaccine under clinical trial is developed based on the known attenuated DENV-2 strain PDK53 (6, 10, 15, 16) . Additionally, recombinant DENV-4 with a deletion of 30 nucleotides in the 3= UTR (DEN4⌬30) has been successfully utilized as a backbone for chimeric dengue vaccine development (11, (17) (18) (19) (20) . Generally, the well-characterized atten-rogen) into BHK-21 cells grown in 60-mm-diameter culture dishes. Supernatants were then harvested at about day 5 posttransfection, when typical cytopathic effects (CPE) were observed, and clarified by low-speed centrifugation. Working virus stocks (named ChinDENV) were prepared by amplification of the transfection harvest for one passage on Vero or PHK cells and stored in aliquots at Ϫ80°C until use. Virus titers were determined by standard plaque assay on BHK-21 cells.
Nucleotide sequencing. Viral RNA was isolated using an RNeasy minikit (Qiagen), and the genome cDNA was obtained by reverse transcription (RT) using SuperScript III (Invitrogen). For determination of consensus sequence, PCR products were directly sequenced in both directions using virus-specific primers. The 5= and 3= termini were sequenced using 5= and 3= rapid amplification of cDNA ends (RACE). Sequence fragments were assembled into a consensus sequence with DNA STAR software, version 7.0.
Growth curves. Growth curves were done by infecting confluent BHK-21, C6/36, Vero, or PHK cells in a 12-well plate at a multiplicity of infection (MOI) of 0.01. The inoculum was removed after 1 h of adsorption, and culture medium was added. Cell supernatants were collected at successive 24-h intervals postinfection. Yields of virus in each sample were then quantitated by plaque assay on BHK-21 cells. Briefly, BHK-21 cells in 12-well plates were infected with a 10-fold serial dilution of viruses. The plates were incubated at 37°C for 1 h with gentle rocking every 15 min. The supernatant was removed, and cells were overlaid with 1% low-meltingpoint agarose (Promega) in DMEM containing 2% FBS. After further incubation at 37°C for 4 days, the cells were fixed with 4% formaldehyde and stained with 0.2% crystal violet to visualize the plaques.
IFA. Indirect immunofluorescence assays (IFA) were performed as follows. Briefly, confluent BHK-21 cells grown in 60-mm-diameter culture dishes containing a 1-cm 2 coverslip inside were infected with viruses at an MOI of 0.01. At 48 h postinfection, the coverslips containing infected cells were removed and directly used for IFA analysis. The cells seeded on the coverslip were fixed with ice-cold acetone and incubated with primary antibodies (monoclonal antibody [MAb] 4AD 5 F 5 D 5 D 6 for JEV E protein, MAb 2B8 for DENV E protein [27] , or JN1 for JEV NS1 protein [Abcam]) or serum of mice at 37°C for 1 h. Cells were washed three times with phosphate-buffered saline (PBS) and then incubated with secondary antibodies conjugated to Alexa Fluor 488 (Invitrogen) in PBS for 30 min at 37°C. Fluorescent cells were examined using a fluorescence microscope (Olympus).
Genetic-stability assay. The chimeric virus ChinDENV was serially passaged in PHK cells at an MOI of 0.01. The complete genome sequence and plaque phenotypes of ChinDENV virus of passages 3, 9, and 15 were assessed as described above.
Neutralization assay. Neutralizing antibody titers were determined by a constant virus-serum dilution 50% plaque reduction neutralization test (PRNT 50 ). Briefly, a 1:10 dilution of serum was prepared in DMEM containing 2% FBS and then heat inactivated for 30 min at 56°C. Serial 2-fold dilutions of inactivated sera were mixed with equal volumes of DENV-2 in DMEM supplemented with 2% FBS to yield a mixture containing approximately 250 PFU of virus/ml. After incubation at 37°C for 1 h, 200-l volumes of the virus-antibody mixtures were added to wells of 12-well plates containing confluent monolayers of BHK-21 cells. The concentration of infectious virus was determined using the plaque assay described above. The endpoint neutralization titer was calculated by the method of Reed and Muench (29) .
Mouse experiments. Research involving animals was approved by and carried out in strict accordance with the guidelines of the Experimental Animal Welfare and Ethics Committee of Beijing Institute of Microbiology and Epidemiology. For neurovirulence tests, groups of 2-day-old and 4-week-old BALB/c mice were inoculated by the intracerebral (i.c.) route with 10-fold dilutions of ChinDENV and its parent viruses, respectively. Animals were monitored for 21 days after inoculation. Any mice found in a moribund condition were euthanatized and scored as dead. Virus doses inducing a 50% mortality rate were calculated using the method of Reed and Muench. Average survival times (AST) were calculated for animals that succumbed to infection.
Immunogenicity was assessed by subcutaneous (s.c.) inoculation of various doses of ChinDENV virus diluted in DMEM plus 2% FBS into 4-week-old female BALB/c mice. The mice were bled by tail vein puncture 1 day prior to and periodically after immunizations at 2, 4, and 6 weeks postimmunization. The sera were stored at Ϫ20°C for determination of IgG antibodies by IFA and neutralizing antibodies by PRNT 50 .
Additionally, groups of 4-week-old female BALB/c mice (n ϭ 10) were first immunized with 6.85 log 10 PFU of JEV live vaccine SA14-14-2 or PBS by the s.c. route, and then 14 days later, all the animals were immunized with the same dose of ChinDENV. At 28 and 42 days after primary immunization, titers of neutralization antibody against DENV-2 in sera from each animal were measured by using standard PRNT as described above.
For the protection assay, heat-inactivated sera from mice immunized with ChinDENV were mixed with equal volumes of DENV-2 (D2-43 strain) diluted in DMEM supplemented to yield a mixture containing approximately 500 PFU (ϳ100 LD 50 s) of virus/ml. The virus-antibody mixtures were incubated at 37°C for 1 h and then injected by the i.c. route into groups of 2-day-old BALB/c suckling mice (n ϭ 9). Animals were then monitored for 15 days after inoculation.
JEV challenge experiments.
For the cross protection study, groups of 4-week-old BALB/c mice were inoculated by the s.c. route with 10 5 PFU of ChinDENV. Equal doses of JEV (SA14-14-2) and PBS were set as controls. Four weeks after the initial vaccination, all the mice were intraperitoneally (i.p.) challenged with 10 5 PFU (10 LD 50 s) of JEV SX-06 as described in the relevant figure legends. Signs of illness and death were monitored for at least 15 days. Groups of three virus-immunized or PBS-immunized mice were anesthetized, and blood was collected by retro-orbital bleeding and subjected to neutralizing antibody titration by plaque assay. Spleens were taken after cervical dislocation for evaluation of cellular immune response (described below).
Cellular immune responses. Cellular immune responses were assessed in splenocytes by the gamma interferon (IFN-␥) or interleukin 2 (IL-2) enzyme-linked immunosorbent spot (ELISPOT) mouse set (BD Biosciences) according to the manufacturer's protocol. Briefly, spleens excised from anesthetized animals were thawed and washed with Hanks balanced salt solution (HBSS). The cells were then centrifuged at room temperature at 2,500 rpm for 15 min without braking, followed by two washes with HBSS. Then, the cells were resuspended in RPMI 1640 containing 10% FBS and diluted to a working concentration of 100 million cells per ml. For ELISPOT analysis, 10 million cells per well were seeded with the appropriate antigen stimulation in 96-well tissue culture dishes coated with 5 mg/ml of IFN-␥ or IL-2 capture monoclonal antibody. Nonstimulated and concanavalin A (5 g/ml; Sigma-Aldrich)-stimulated cells were used as negative and positive controls, respectively. The cells were then cultured for 36 h at 37°C and 5% CO 2 . Plates were washed, and biotinylated anti-mouse IFN-␥ or IL-2 antibody was added to each well and incubated for 2 h at room temperature. Thereafter, the plates were washed and incubated for 1 h at room temperature with streptavidinhorseradish peroxidase (streptavidin-HRP). Finally, AEC substrate solution (BD Biosciences) was added and spots were counted with an ImmunoSpot analyzer (Cellular Technology Ltd.). Assay results are expressed as the value obtained by the following: (number of spots in experimental well Ϫ number of spots in medium control)/10 7 cells. Monkey experiments. All experimental procedures involving rhesus monkeys were performed under sodium pentobarbital anesthesia by trained technicians, and all efforts were made to ameliorate the welfare and to minimize animal suffering in accordance with the recommendations in The Use of Non-Human Primates in Research (30) .
(i) Immunization and challenge of rhesus monkeys. Fourteen monkeys, weighing 3.4 to 5.0 kg, were prescreened for negativity for antibodies against DENV by IFA. Animals were randomly divided into four groups and immunized s.c. in the deltoid region with 0.5 ml of ChinDENV containing 3.0, 4.0, or 5.0 log 10 PFU or were sham inoculated with PBS. Blood was collected daily for 10 days to detect viremia. Blood samples for neutralizing-antibody tests were taken before immunization (day Ϫ1) and then on days 15, 20, 30, 50, and 63 postimmunization. On day 64 postimmunization, all the immunized monkeys plus unimmunized controls were challenged by s.c. inoculation of 0.5 ml containing 5 log 10 PFU of DENV-2 (TSV-01 strain). For the following 9 days, blood was collected for determination of viremia. Neutralizing-antibody levels in serum were measured by neutralization assay described above on days 15 and 30 postchallenge.
(ii) Viremia determination. Viremia in monkeys was measured by quantitative real-time reverse transcriptase PCR (qRT-PCR). Virus titer was expressed in log 10 PFU/ml. The number of PFU in serum detected was calculated by generating a standard curve from 10-fold dilutions of RNA isolated from a serum sample containing a known number of PFU, the titer of which was determined by plaque assay on BHK-21 cells as described above. Briefly, viral genomic RNA was extracted from 200 l of serum or an equal volume of sample serum by using the PureLinkTM RNA minikit (Invitrogen, USA) according to the manufacturer's instructions. RNA was eluted in 50 l of RNase-free water, aliquoted, and stored at Ϫ80°C until use. The primers (5=-CAGGCTATGGCACTGTCACGA T-3= and 5=-CCATTTGCAGCAACACCATCTC-3=) and probe (5=-CTC TCCGAGAACGGGCCTCGACTTCAA-3=) were designed using the program Primer ExpressTM (PE Applied Biosystems, USA). The target region for the assays was based on the E protein region of the genome of DENV-2. A TaqMan assay probe was 5= labeled with the reporter dye 6-carboxyfluorescein (FAM) and labeled at the 3= end with the quencher dye 6-carboxytetramethylrhodamine (TAMRA). qRT-PCR was performed by using a One Step PrimeScript RT-PCR kit (TaKaRa, Japan). The 25-l reaction mixtures were set up with a 0.5 M concentration of each primer (qDVEF and qDVER, respectively), 0.25 M probe, and 5 l of RNA. Thermocycling programs consisted of 42°C for 5 min, 95°C for 10 s, and 40 cycles of 95°C for 5 s and 60°C for 30 s.
Statistic analysis. For survival analysis, Kaplan-Meier survival curves were analyzed by a log rank test using standard GraphPad Prism software, version 5.0.
RESULTS

Engineering and characterization of the chimeric ChinDENV.
To assess the potential of the infectious cDNA clone derived from JEV SA14-14-2 to serve as a vector for vaccine development, we engineered a chimeric DENV-2 (termed ChinDENV) cDNA clone containing the structural genes of DENV-2 strain D2-43, a representative strain of the Asia 1 genotype, using a subgenomic replicon of JEV SA14-14-2 (31) as the genetic backbone. ChinDENV retained the prM signal peptide of JEV as well as the last three amino acids at the terminus of the E protein to ensure efficient cleavage at the C-prM junction and E-NS1 junction, respectively (Fig. 1) .
Total RNA transcripts encoding ChinDENV were transfected in BHK-21 cells, and immunostaining assays with specific monoclonal antibodies characterized the recovered ChinDENV expressing the E protein of DENV-2 and NS1 protein of JEV (Fig.  2A) . The recovered ChinDENV caused typical cytopathic effects in BHK-21 cells almost the same as parental DENV, producing a homogeneous population of plaques which were Ϸ0.5 mm in diameter, approximately half the size of those of parental JEV (Fig.  2B) . RT-PCR analysis and full-genome sequencing confirmed that the prM-E gene of DENV-2 was successfully engineered into the genome of JEV SA14-14-2 as expected.
Full-genome sequencing showed that there were seven nucleotide substitutions between ChinDENV and parental DENV-2 in the prM-E genes, and four of them resulted in amino acid changes, including prM-28 Gly to Gln, prM-55 Leu to Phe, prM135 Met to Ile, and E402 Phe to Ile. Within the UTRs and capsid protein as well as nonstructural protein genes, there were four nucleotide differences (nucleotide positions 473, 3200, 3465, and 10843) between ChinDENV and JEV SA14-14-2, all of which were silent and did not cause amino acid substitutions.
Subsequently, the growth efficiencies of ChinDENV and its parental viruses were examined in mammalian Vero and mosquito C6/36 cells (Fig. 2D) . The results showed that ChinDENV replicated efficiently in Vero and C6/36 cells and peaked at 72 and 48 h postinfection, with titers of 10 5.8 PFU/ml and 10 6.9 PFU/ml, respectively. ChinDENV replicated slightly more efficiently than parental DENV-2, whereas both of them replicated less efficiently than JEV in both cells. The growth kinetics of ChinDENV was then determined in primary hamster kidney (PHK) cells, the certified cell bank intended for manufacturing ChinDENV. As shown in Fig. 2D , ChinDENV and DENV-2 exhibited very similar kinetics of virus production, with the same peak titer, approximately 10 6.3 PFU/ml. Taken together, these results demonstrate that the rescued ChinDENV chimera possesses the designed genomic structure, expresses DENV-specific antigens, shows a smallplaque phenotype, and replicates efficiently in different cell lines.
Genetic and plaque phenotypic stability of ChinDENV. To assess the phenotype and genetic stability of ChinDENV during sequential passage in vitro, ChinDENV recovered from transfected cells (passage 0) was passaged up to 15 times in PHK cells. Viruses harvested at passages 3, 9, and 15 were subjected to a plaque forming assay and complete-genome sequencing in comparison with that of passage 0. The small-plaque phenotype of ChinDENV in BHK-21 cells remained unchanged at each passage (Fig. 2C) , indicating that there were no plaque variants overgrowing the original parent population. Only a single nucleotide mutation at position 2173 in the E gene occurred at passage 15, leading to an amino acid change from Gln to Arg. Another silent nucleotide change at position 8666 in the NS5 gene was observed at passage 9. These data indicate that the chimeric virus ChinDENV exhibits a genetic and plaque phenotypic stability during in vitro passage.
Virulence of the chimeric ChinDENV in mice. The JEV vaccine strain SA14-14-2 retains a degree of neurotropism in suckling mice (21) . To make sure ChinDENV does not exceed its parental virus in neurovirulence, groups of 2-day-old BALB/c mice were inoculated with serial 10-fold dilutions of ChinDENV and its parental viruses, JEV SA14-14-2 and DENV-2 D2-43, by the i.c. route. All the infected animals were then observed for at least 21 days for signs of illness and death. As shown in Table 1 , the LD 50 of ChinDENV was 245.47 PFU, approximately 115-fold and 50-fold higher than those of JEV SA14-14-2 and DENV D2-43. Additionally, we also found that neither the ChinDENV chimera nor its parental viruses were lethal for 3-to 4-week-old BLAB/c mice inoculated at a dose of 10 5.0 PFU by the i.c. or i.p. route (data not shown). These results indicate that ChinDENV exhibits greatly reduced neurovirulence in suckling mice compared with those of its parental viruses and retains avirulence to immunocompetent adult mice.
Immunogenicity and protection in mice. To assess the immunogenicity of ChinDENV in mice, groups of 4-week-old BALB/c mice were immunized with various doses (10 4.8 and 10
5.8 PFU per mouse) of ChinDENV by the s.c. route. Serum IgG and neutralizing antibodies against DENV-2 were measured by IFA and PRNT at 2, 4, and 6 weeks after immunization as previously described (32) . All mice had seroconversion at 2 weeks postimmunization, and IgG antibody levels increased rapidly (Fig. 3A) . High levels of IgG antibodies remained stable until day 42 in mice receiving either a low or high dose (10 4.8 or 10 5.8 PFU) of ChinDENV. Importantly, DENV-specific neutralizing antibodies were induced in all mice immunized with ChinDENV in a dose-dependent manner. The geometric mean titers (GMTs) of neutralizing antibody induced by low and 3B ).
To clarify whether preimmunization of JEV interferes with the immunogenicity of ChinDENV, mice immunized with JEV SA14-14-2 were subjected to a second immunization with the same dose of ChinDENV. As shown in Table 2 , in mice immunized with JEV SA14-14-2, high neutralization antibodies against DENV-2 were successfully induced by the second ChinDENV immunization. However, the peak titer (55.00 Ϯ 8.85) at 42 days after primary immunization in the JEV-preimmunized mice was slightly lower than that in naive mice (84.00 Ϯ 17.33). And no neutralization antibody was detected in the PBS control group, as expected.
Since no ideal immunocompetent-mouse model was currently available for DENV challenge, we initially evaluated the protection efficacy of ChinDENV antisera in the established sucklingmouse model as previously described (27) . Complete protection was observed for the group of animals inoculated with antisera from the ChinDENV-immunized mice, whereas all control mice died within 5 to 9 days postinoculation (data not shown). Taken together, these results demonstrate that immunization with a single dose of ChinDENV could induce a neutralizing antibody response against DENV-2 that conferred full protection against lethal DENV-2 challenge in suckling mice.
Viremia, immunogenicity, and protection in nonhuman primates. Attenuation of ChinDENV was further evaluated in rhesus monkeys, the most suitable model for preclinical evaluation of safety of DENV infections for humans (33, 34) . Three groups of adult rhesus monkeys were inoculated s.c. with ChinDENV at doses of 1 ϫ 10 3 , 1 ϫ 10 4 , and 1 ϫ 10 5 PFU per animal. Viremia in monkeys was then determined by real-time RT-PCR for 10 days postinjection. All the animals injected with wild-type (wt) DENV-2 exhibited continual viremia (mean duration, 3.5 days), with a peak titer of 10 2.75 PFU/ml following DENV challenge. However, ChinDENV failed to produce any detectable viremia in any inoculated monkeys (Table 3) . No signs of disease or clinical manifestation were observed in any of the ChinDENV-injected animals throughout the experiments. These results strongly demonstrate the excellent safety profile of ChinDENV in nonhuman primates.
Next, we determined the neutralizing antibody response induced by the single dose of ChinDENV in monkeys. As shown in Table 4 , all the ChinDENV-immune monkeys developed neutralizing antibodies to DENV-2 from day 15 until day 50 postimmunization in a dose-dependent manner. Monkeys receiving high and middle doses of ChinDENV attained peak GMTs of 184 and 204 on day 20 after inoculation, respectively. Animals immunized with the low dose of ChinDENV also developed strong neutralizing antibodies on day 30 postimmunization, with a GMT of 82. No neutralizing antibody was detected for the control animals immunized with PBS, as expected.
To assess the in vivo protective efficacy, all the vaccinated animals were challenged with wt DENV-2 on day 63 postimmunization, and viremia was monitored for 10 days thereafter. As shown in Table 5 , control animals immunized with PBS exhibited continual viremia (mean duration, 5.5 days), with a peak titer of 10 2.25 PFU/ml following wt DENV-2 challenge. All the animals receiving high and middle doses (10 5 and 10 4 PFU) of ChinDENV developed no viremia following wt DENV-2 challenge; only one animal (R0085) immunized with a low dose (10 3 PFU) of ChinDENV developed low-level, transient viremia (Table 5 ). These observations showed that the single dose of ChinDENV immunization significantly protected against wt DENV-2-induced viremia in nonhuman primates. Additionally, the anamnestic antibody response after virus challenge was analyzed in the sera collected at days 15 and 30. It is noteworthy that all ChinDENV-immune monkeys developed a significant (ϳ4-to 6-fold) increase in serum neutralizing antibody titer after DENV-2 challenge, indicating that DENV-2 challenge had stimulated a strong anamnestic immune response (Table 4) . Together, these results strongly demonstrate that a single immunization with ChinDENV successfully induced a robust protective immune response in nonhuman primates.
Protection against lethal JEV challenge in mice. Clinical trials have demonstrated that YFV-specific cellular immune response could be induced by the YFV-based CYD vaccination (35) . In this study, to make sure that the potential protective immunity against JEV was conferred by ChinDENV immunization, groups of 4-week-old BALB/c mice immunized with ChinDENV were challenged with lethal JEV challenge. The same dose of SA14-14-2 was also immunized as controls together with PBS. All the mice were then subjected to a 15-day period of observation for signs of death. All the mice immunized with SA14-14-2 survived, and all PBS controls died within 9 days postinfection, as expected (Fig. 4A) . Significantly, none of the ChinDENV-vaccinated animals died from wt JEV challenge. This result demonstrates that a single immunization with ChinDENV could induce complete protection against lethal JEV challenge.
To further investigate the putative roles of the humoral and cellular immune responses in the protection against JEV challenge, PRNT against JEV and DENV-2 were assayed, respectively. As shown in Fig. 4B , ChinDENV immunization induced significant neutralizing antibodies (GMT, 1:33) against DENV-2, whereas the titer of neutralizing antibody against JEV was relatively low (GMT, 1:11). This result indicates that the ChinDNEV-induced protection may not be attributable to the humoral immune response to the chimeric DENV structural proteins. We next ascertained whether the cell-mediated immune response accounts for the cross protection against JEV infection. Splenocytes from immunized and PBS control mice were harvested 4 weeks postimmunization and were stimulated with JEV or DENV-2 and its corresponding replicons. The production of IFN-␥ and IL-2 was then assayed by ELISPOT assay. Significant levels of IFN-␥ and IL-2 production were induced by either JEV or JEV replicons in ChinDENV-immunized mice, whereas neither DENV-2 nor DENV-2 replicons induced the secretion of IFN-␥ or IL-2 in ChinDENV-immunized mice (Fig. 4C) . These data indicate that the significant protection against JEV infection induced by ChinDENV is probably associated with an efficient cellular immune response to the JEV nonstructural proteins of ChinDENV.
DISCUSSION
Utilizing reverse genetics, we obtained a chimeric dengue virus, ChinDENV, by replacement of the prM-E coding region of JEV vaccine strain SA14-14-2 with the corresponding segment of DENV-2. Cleavage of the N-terminal signal sequence of prM by a host cellular peptidase requires prior removal of the C protein from this signal sequence by the viral NS2B/3 protease (36) (37) (38) . These coordinated cleavage events are believed to play an important role in the process of the assembly of flavivirus virions. The C termini of the E proteins of all members of the Flaviviridae family have similar organizations (39) and consist of two antiparallel transmembrane helices (TM1 and TM2). The TM2 helix serves as an internal signal sequence for the synthesis of the first nonstructural protein, NS1 (40) . As shown in Fig. 1B , the last and antepenultimate C-terminal amino acids of flavivirus E proteins are highly conserved, indicating that these amino acids are likely to play an important role in efficient cleavage of the E-NS1 junction. Thus, to ensure proper processing of prM and E proteins of DENV-2, the signal sequence of JEV between C and prM as well as the last three C-terminal amino acids of the JEV E protein were retained in the ChinDENV chimera (Fig. 1B) . As expected, the resulting viable ChinDENV was characterized by the chimeric structure of the genome, and the proteins of ChinDENV appeared to be properly processed, with the E protein retaining the antigenic properties of DENV-2 ( Fig. 2A) . It was also observed that ChinDENV displayed a small-plaque phenotype in BHK-21 cells, similar to that of prM-E donor virus, but its plaque size was significantly reduced compared to that of JEV. We further found that ChinDENV grew equally as well as the parent virus DENV-2 in various cell lines, with decreased peak replication titers compared with JEV. These results are consistent with the previous observations that chimeras exhibited growth characteristics similar to those of the viruses contributing structural protein genes (5, 41) , indicating that the reduction in plaque size and replication efficiency for ChinDENV compared to JEV are likely to be determined partly by the donor prM-E genes. In addition, the chimerization itself has been proved to contribute to the attenuation of chimeras (10, (42) (43) (44) (45) (46) (47) (48) (49) (50) . Notably, the chimeric virus ChinDENV replicated efficiently in Vero and PHK cells, both of which are certified for vaccine production. Additionally, ChinDENV reached a peak titer of 10 7.7 PFU/ml in PHK cells after optimization. Serial passaging of ChinDENV in Vero cells resulted in a single amino acid change (Q400R) in the E protein of ChinDENV at passage 15 and a single silent nucleotide mutation (C8666T) within NS5 gene at passage 9. Neither mutation affected the phenotypic trait of plaque size of ChinDENV (Fig. 2C) . These results suggest that the ChinDENV chimera can be convenient for scale-up and industrialization.
Loss of or low mouse virulence is an important attenuation marker for flaviviruses. In our study, the chimera ChinDENV exhibited a significant attenuation phenotype, with an i.c. LD 50 about 115-fold and 50-fold higher than those of its parental viruses JEV SA14-14-2 and DENV-2 D2-43, respectively. In addition, lack of neuroinvasiveness of ChinDENV as well as its parental viruses in the adult mouse demonstrates that ChinDENV does not exceed its parental viruses in peripheral virulence. Attenuation of ChinDENV was further assessed by determining its viremia profile in rhesus monkeys, which is correlated closely to the phenotype of attenuation in humans (51, 52) . No viremia was detected in any ChinDENV-inoculated monkey, even at a high dose (10 5 PFU) (Table 3) , while monkeys developed high levels of viremia following inoculation with the same dose of wt DENV-2 (Table 3) . These data indicate a favorable safety profile for ChinDENV.
A single dose of ChinDENV stimulated both IgG and neutralizing antibodies against DENV-2 in mice, and passive serum of mice immunized with ChinDENV conferred complete protection against DENV-2 challenge in suckling mice. In rhesus monkeys, the chimeric ChinDENV rapidly elicited a neutralizing antibody response to wt DENV-2 in a dose-dependent manner (Table 4) . It was observed that the monkeys immunized with high and middle doses of ChinDENV showed no signs of viremia postchallenge, and the mean peak titer and mean duration of viremia in low-dose groups were significantly reduced compared with those of the PBS-immunized group after challenge with wt DENV-2 (Table 5) . Especially, we found that one monkey with viremia postchallenge in the low-dose group had a neutralizing antibody titer of 1:74. Sanofi's recent phase 2b trial also showed a lack of protective efficacy against DENV-2 infection despite the induction of reasonable levels of neutralizing antibodies against all four serotypes on vaccination (13) . The explanation for this phenomenon remains a puzzle.
Recall immunity after challenge plays a critical role in protection against flavivirus (53) . The role of anamnestic responses for reducing viremia after challenge has been supported by previous studies (54) (55) (56) (57) (58) (59) (60) . We also found that monkeys immunized with ChinDENV and challenged s.c. with wt DENV-2 had dramatic increases in serum neutralizing antibodies, suggesting a good memory component in ChinDENV immunity. However, the presence of an anamnestic immune response, even in animals that developed no detectable viremia, demonstrating limited or localized viral replication, has been shown in those animals. Nevertheless, the boost in antibody responses postchallenge would guarantee that upon natural exposure, vaccinated individuals would respond with a rapid and robust immune response. Taken together, these results demonstrate that the chimeric virus ChinDENV exhibits a satisfactory balance between attenuation and immunogenicity against DENV-2 in mice and monkeys.
JE vaccination has been proven to be the only effective measure for disease control (61) , and the live vaccine SA14-14-2 is widely used in most areas where JE is endemic. Interestingly, a single immunization with ChinDENV provided full protection against lethal JEV challenge in BALB/c mice (Fig. 4) . The existence of cross protection between heterologous but closely related members of the Flaviviridae family has been reported (62) (63) (64) (65) (66) . Neutralization assay showed that the titer of neutralization antibody against JEV was relatively low and may not account for the in vivo protection. The contribution of the NS1-induced immune response should not be ruled out, since flavivirus NS1 protein has been shown to induce protective immune responses in animals (67) (68) (69) (70) (71) (72) (73) . Notably, immunization with ChinDENV elicited significantly increased JEV antigen-specific T cell responses (IFN-␥ and IL-2), suggesting a possible role for cellular immunity in the defense against JEV challenge in ChinDENV-immunized mice. T lymphocytes have been found to be necessary for protection from WNV (74) and DENV (75, 76) infections in animal models. Most identified flavivirus T cell epitopes reside in the nonstructural proteins (77) (78) (79) (80) , the majority of which concentrated within the NS3 protein (reviewed in reference 81). Although the contribution of cellular immune responses to recovery from JEV infection remains unclear, a requirement for both CD4 ϩ and CD8 ϩ T cells to control infections in the central nervous system has also been shown for JEV (82) . Collectively, these data suggest that ChinDENV can afford a cross protection against lethal JEV challenge in mice in association with both the humoral and cellular immune responses.
The DENV vaccine candidate ChinDENV described here represents a significant advancement for dengue vaccine development. First, ChinDENV utilizes the JE vaccine SA14-14-2, which has demonstrated an ideal safety profile in large-scale clinical usage, as the genetic backbone. Meanwhile, for YFV-17D, the backbone for CYD in clinical trials, vaccination-associated adverse events have been reported (83) (84) (85) (86) (87) . Second, the Sanofi Pasteur's CYD2 vaccine carries the prM-E genes of Asian genotype I of DENV-2 (PUO-218 strain). The antigenic mismatch between the CYD2 vaccine virus and the DENV-2 circulating in Thailand currently has been partially attributed to the failure of protection in the clinical trials in Thailand (13) . ChinDENV carries the protective antigens of DENV-2 strain D2-43 (Asian genotype II). In particular, there are five amino acid substitutions in the E protein (residues 71, 141, 164, 402, and 484) between ChinDENV and CYD2. Several of them are solvent exposed and involve potential neutralizing antibody epitope recognition (88) . Third, JEV and DENV are currently cocirculating in many Asian countries, where the socioeconomic burden of both diseases is significant. A vaccine candidate that could protect against both DENV and JEV will be highly attractive.
In summary, the chimeric virus ChinDENV is characterized by a highly attenuated profile in mice, a lack of viremia in rhesus monkeys, satisfactory immunogenicity, and protective efficacy for DENV-2 infection in mice and monkeys. In particular, the chimera is capable of providing cross protection from JEV infection in mice. This novel live attenuated chimeric dengue vaccine based on JEV vaccine shows great potential for further development.
